Although T-DXd has not yet received an approved indication in the first line setting for HER2 mutant NSCLC, the DESTINY-Lung04 study in first line setting is ongoing, and its data have not yet been published. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.